Palmitoyl Dipeptide-6 vs Cagrilintide
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6GLP-1 / Weight Loss Agonists
Cagrilintide- Summary
- Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
- Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
- Half-Life
- Not applicable (topical)
- ~7–10 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 0.005–0.05% in formulation
- 0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
- Frequency
- Once or twice daily
- Once weekly
- Key Benefits
- Increases skin firmness and density
- Stimulates fibronectin and collagen IV production
- Strengthens the dermal-epidermal junction
- Reduces skin sagging in mature skin
- Improves skin texture and smoothness
- Supports extracellular matrix integrity
- ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
- Synergistic appetite suppression complementing GLP-1 receptor agonists
- Reduces post-meal glucagon excursions improving glycemic control
- Slows gastric emptying contributing to prolonged satiety
- Once-weekly dosing via subcutaneous injection
- Potential for greater weight loss than semaglutide monotherapy
- Side Effects
- Generally well-tolerated
- Rare mild skin irritation in sensitive individuals
- No known systemic effects at cosmetic concentrations
- Nausea (most common, especially during titration)
- Vomiting
- Decreased appetite
- Diarrhea
- +2 more
- Stacks With
- —
- —